|
Federal
Register Notices > Notice of
Application - 2006
>
Chattem Chemicals, Inc.
FR Doc E6-20339 [Federal Register: December 1, 2006 (Volume 71, Number 231)]
[Notices] [Page 69589-69590] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr01de06-102]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR),
this is notice that on April 25, 2006, Chattem Chemicals, Inc., 3801 St. Elmo
Avenue, Building 18, Chattanooga, Tennessee 37409, made application by renewal
to the Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in schedule I
and II:
|
Drug
|
Schedule
|
|
N-Ethylamphetamine (1475)
|
I
|
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
|
4-Methoxyamphetamine (7411)
|
I
|
|
Difenoxin (9168)
|
I
|
|
Dihydromorphine (9145)
|
I
|
|
Amphetamine (1100)
|
II
|
|
Methamphetamine (1105)
|
II
|
|
Methylphenidate (1724)
|
II
|
|
Pentobarbital (2270)
|
II
|
|
Secobarbital (2315)
|
II
|
|
Codeine (9050)
|
II
|
|
Dihydrocodeine (9120)
|
II
|
|
Oxycodone (9143)
|
II
|
|
Hydromorphone (9150)
|
II
|
|
Diphenoxylate (9170)
|
II
|
|
Hydrocodone (9193)
|
II
|
|
Meperidine (9230)
|
II
|
|
Dextropropoxyphene, bulk (non-dosage forms) (9273)
|
II
|
|
Morphine (9300)
|
II
|
|
Thebaine (9333)
|
II
|
|
Opium Extracts (9610)
|
II
|
|
Opium Fluid Extract (9620)
|
II
|
|
Opium Tincture (9630)
|
II
|
|
Opium, Granulated (9640)
|
II
|
|
Oxymorphone (9652)
|
II
|
|
Noroxymorphone (9668)
|
II
|
|
Opium, Powdered (9639)
|
II
|
|
Alfentanil (9737)
|
II
|
|
Sufentanil (9740)
|
II
|
|
Fentanyl (9801)
|
II
|
The company plans to manufacture the listed controlled substances in bulk for
distribution to its customers.
Any other such applicant and any person who is presently registered with DEA
to manufacture such a substance may file comments or objections to the issuance
of the proposed registration pursuant to 21 CFR Sec. 1301.33(a).
[[Page 69590]]
Any such written comments or objections being sent via regular mail should be
addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, Washington, DC 20537,
Attention: DEA Federal Register Representative/ODL; or any being sent via
express mail should be sent to DEA Headquarters, Attention: DEA Federal Register
Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301;
and must be filed no later than January 30, 2007.
Dated: November 21, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-20339 Filed 11-30-06; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|